Pretreatment characteristics of the patients who had a sustained response and those without sustained response to combination therapy
| Patient characteristics . | Sustained responses (n = 14) . | Not sustained responses (n = 25) . | P . |
|---|---|---|---|
| Mean age, y (range) | 39 (27-65) | 40 (22-63) | NS |
| Mean ALT, IU/mL (range) | 168 (56-441) | 116 (46-234) | .028 |
| Median HCV-RNA, MEq/mL (range) | 2.5 (< 0.2-43.0) | 4.9 (< 0.2-33.0) | NS |
| HCV | .047 | ||
| HCV 1* (%) | 8 (57) | 22 (88) | |
| HCV 2 or 3 (%) | 6 (43) | 3 (12) | |
| Outcome of previous IFN monotherapy (%) | |||
| Nonresponse | 7 (50) | 17 (68) | NS |
| Transient response | 7 (50) | 8 (32) | NS |
| Patient characteristics . | Sustained responses (n = 14) . | Not sustained responses (n = 25) . | P . |
|---|---|---|---|
| Mean age, y (range) | 39 (27-65) | 40 (22-63) | NS |
| Mean ALT, IU/mL (range) | 168 (56-441) | 116 (46-234) | .028 |
| Median HCV-RNA, MEq/mL (range) | 2.5 (< 0.2-43.0) | 4.9 (< 0.2-33.0) | NS |
| HCV | .047 | ||
| HCV 1* (%) | 8 (57) | 22 (88) | |
| HCV 2 or 3 (%) | 6 (43) | 3 (12) | |
| Outcome of previous IFN monotherapy (%) | |||
| Nonresponse | 7 (50) | 17 (68) | NS |
| Transient response | 7 (50) | 8 (32) | NS |
NS indicates not significant.
Includes 1 patient with genotype 4.